Traumatic Brain Injury Clinical Trial
Official title:
Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD: Neurokinetics, Inc, iPAS
The long term goal for the Traumatic Injury Research Program (TIRP) is testing of novel
devices for the identification and longitudinal assessment of traumatic brain injury (TBI).
DoD (United States Department of Defense) has now tasked TIRP with the test and evaluation of
these devices to assess reliability and validity. The objective of this effort is to test the
reliability of the NKI, Inc, (NeuroKinetics, Inc) i-PAS device using a test/re-test protocol
with healthy controls.
The research design is test/re-test, with three assessments obtained on three separate
visits. This will allow the assessment of reliability of both the device and the measure(s)
that are computed from the input signals. Participants will be Healthy Controls (HC) as
defined in the inclusion exclusion section.
In this initial study, investigators will be administering standardized self-report
instruments (Standard Form 36 - SF36, and Symptom Checklist 90r, or SCL-90r), standard
three-lead EKG. In addition they will administer the NKI i-PAS specific protocol as
delineated by NKI.
Traumatic brain injury is not only a significant medical and operational issue for the
military but is a significant public health issue in the United States. The CDC reports that
1.4 million Americans sustain traumatic brain injuries each year. Of these 50,000 die,
235,000 are hospitalized and 1.1 million are treated and released from the emergency
department. Among children fourteen years old and younger, there are an estimated 2685 TBI
deaths per year, 37,000 hospitalizations and 435,000 emergency room visits.
Additionally, the Centers for Disease Control (CDC) also notes that TBI is significantly
under-reported.
Traumatic brain injury is under detected. Neuropsychological evaluations are often
nondisclosing The DoD has invested considerable funds in the development of devices for use
in acute and chronic assessment of TBI. Unfortunately none of these devices have been tested
systematically to establish reliability of the equipment, reliability of the signals
obtained, or reliability of the measures derived from the signals obtained.
The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for
eye tracking with the following properties: a head mounted display, a sampling rate of 100
frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil
area measurement with a spatial resolution less than 0.1 o. The testing protocol includes:
optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random
horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal),
self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time,
gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical
horizontal. Several quantitative measures are computed from the data acquired in each test,
and these measures are then employed in a multivariate diagnostic assessment.
It is important to distinguish between a device, a signal and a measure. As used here, the
term device refers to a hardware technology used to obtain a signal. In the case of
neurodiagnostic devices, the signal is usually a measurement of voltage as a function of
time. Examples of signals pertinent to the present discussion include the electrocardiogram
(providing an assessment of autonomic nervous system status), the electroencephalogram,
evoked potentials, event related potentials, balance records and eye movement trajectories. A
clear distinction must be drawn between a signal, typically a voltage record, and a measure
which is a number that is computed from the voltage signal. Reliability and validity must be
investigated separately for each measure For example, a dozen measures may be calculated from
the same EEG voltage signal. The reliability and validity of each measure must be evaluated.
The objectives of this initial study are limited. The investigators address the question: are
the measures obtained from the NeuroKinetics iPAS eye tracking system longitudinally stable
in a clinically stable healthy participant? These measures are described in a subsequent
section.
A single channel ECG will be acquired and measures of heart rate variability will be
calculated from this signal. Measures of heart rate variability provide an indirect surrogate
measure of complex multifactorial states that can have an impact on psychophysiological
variables. Alterations of heart rate variability (HRV) are associated with pain, attention
and cognitive function and fatigue, all of which can affect neurophysiological measures. High
intra-individual variability in a test-retest study is a warning sign that between recording
changes in the state of the participant rather than reliability failures in the eye tracking
measure may be playing a role in low reliability.
Following consent, eligibility will be established based on head injury history, the score on
the Symptom Checklist 90 (in the Supporting Documents file), the Short Form 36 (in the
Supporting Documents file), and the Defense Veterans Brain Injury Center (DVBIC) Three
Question Screening Tool.
The standard iPAS eye tracking evaluation as described below will be administered and the ECG
will be recorded simultaneously during this process.
A second recording will be obtained within two to six days of the first recording.
A third recording will be obtained at approximately four weeks following the first recording.
This study will establish normal values of neuroassessment measures obtained from healthy
controls and will be used to establish the statistical separation between healthy populations
and clinical populations presenting neuropsychiatric disorders including TBI-positive
patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT05503316 -
The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Terminated |
NCT03698747 -
Myelin Imaging in Concussed High School Football Players
|
||
Recruiting |
NCT05130658 -
Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training
|
N/A | |
Recruiting |
NCT04560946 -
Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI
|
N/A | |
Completed |
NCT05160194 -
Gaining Real-Life Skills Over the Web
|
N/A | |
Recruiting |
NCT02059941 -
Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines
|
N/A | |
Recruiting |
NCT03940443 -
Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
|
||
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Completed |
NCT04465019 -
Exoskeleton Rehabilitation on TBI
|
||
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Recruiting |
NCT03899532 -
Remote Ischemic Conditioning in Traumatic Brain Injury
|
N/A | |
Suspended |
NCT04244058 -
Changes in Glutamatergic Neurotransmission of Severe TBI Patients
|
Early Phase 1 | |
Completed |
NCT03307070 -
Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury
|
N/A | |
Recruiting |
NCT04274777 -
The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
|
||
Withdrawn |
NCT04199130 -
Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI
|
N/A | |
Withdrawn |
NCT05062148 -
Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery
|
N/A | |
Withdrawn |
NCT03626727 -
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
|
Early Phase 1 |